Evidence map›Paper›PMID 25054828›Full record

ArticlePloS one2014

PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.

Lin Wang, Ling Shan, Shaokai Zhang, Jianming Ying, Liyan Xue, Yanling Yuan, Yongqiang Xie, Ning Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2017
    Pooled it
  2. Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).Esophagus : official journal of the Japan Esophageal Society · 2022
    Trial
  3. Review
  4. Review
  5. Review
  6. Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. World journal of gastroenterology · 2017
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lin WangDepartment of Pathology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Ling ShanDepartment of Pathology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Shaokai ZhangDepartment of Epidemiology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Jianming YingDepartment of Pathology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Liyan XueDepartment of Pathology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Yanling YuanDepartment of Pathology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Yongqiang XieDepartment of Pathology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Ning LuDepartment of Pathology, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate PIK3CA gene mutations and PIK3CA expression status in Chinese esophageal squamous cell carcinoma (ESCC) patients, and their correlation with clinicopathological characteristics and clinical outcomes.

methodsDirect sequencing was applied to investigate mutations in exons 9 and 20 of PIK3CA in 406 Chinese ESCC patients. PIK3CA expression was evaluated using immunohistochemistry analysis. The associations of PIK3CA gene mutations and PIK3CA expression with clinicopathological characteristics and clinical outcome were examined.

resultsThirty somatic point mutations (30/406, 7.4%) were identified in exon 9 whereas no mutations were detected in exon 20. PIK3CA mutations were not correlated with clinicopathological characteristics or clinical outcomes. However in the ESCC patients with family cancer history, PIK3CA mutations were independently correlated with worse overall survival (multivariate hazard ratio (HR) = 10.493, 95% CI: 2.432-45.267, P = 0.002). Compared to normal esophageal tissue, PIK3CA was significantly overexpressed in cancer tissue (P<0.001). PIK3CA overexpression was independently associated with higher risk of local recurrence (multivariate HR  = 1.435, 95% CI: 1.040-1.979, P = 0.028). In female ESCC patients, PIK3CA overexpression was independently correlated with worse overall survival (multivariate HR  = 2.341, 95% CI: 1.073-5.108, P = 0.033).

conclusionsOur results suggest PIK3CA gene mutation and overexpression could act as biomarkers for individualized molecular targeted therapy for Chinese ESCC patients.

Indexed as

Gene Expression Regulation, NeoplasticPoint MutationAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellChinaClass I Phosphatidylinositol 3-KinasesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagusExonsFemaleHumansMaleBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesPIK3CA protein, human

Identifiers

PMID25054828
PMCPMC4108430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.